Author:
Fujiwara Keiichi,Kiura Katsuyuki,Ueoka Hiroshi,Tabata Masahiro,Hamasaki Shuji,Tanimoto Mitsune
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference11 articles.
1. Tyrosine kinase inhibitors-ZD 1839 (Iressa);Arteaga;Curr. Opin. Oncol.,2001
2. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 (‘Iressa’) a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR);Kris;Lung Cancer,2000
3. Final results of a phase I intermittent dose-escalation trial of ZD 1839 (‘Iressa’) in Japanese patients with various solid tumours;Negoro;Proc. Am. Soc. Clin. Oncol.,2001
4. ZD 1839 (‘Iressa’), a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial;Ranson;J. Clin. Oncol.,2002
5. ZD 1839 (Iressa), an oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor): pharmacokinetic results of a phase I study in patients with advanced cancer;Kelly;Proc. Am. Assoc. Cancer Res.,2000
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献